Sentence examples for multicenter randomised phase from inspiring English sources

The two multicenter, randomised, phase III clinical trials are described in detail elsewhere (Lee et al, 2009a, 2009b).

Imamura et al (2008) conducted a multicenter, randomised phase III trial comparing irinotecan (CPT-11)+S-1 (IRIS) to S-1 alone in advanced gastric cancer patients.

Our group carried out a multicenter randomised phase III trial testing the safety, activity and efficacy of two different schedules of Epirubicin and Paclitaxel (concurrent vs sequential) in advanced breast cancer patients.

Recently, investigators at the University of Chicago have initiated a multicenter, randomised phase II trial of cisplatin gemcitabine and the vascular endothelial growth factor (VEGF) inhibitor bevacizumab, which has shown preliminary evidence of activity in MPM.

A recent multicenter, randomised phase II study, which compared the irinotecan/gemcitabine combination vs irinotecan in NSCLC patients pretreated with taxanes plus cisplatinum, demonstrated a poor antitumour activity of irinotecan (ORR=4.2%) (Georgoulias et al, 2004) as already reported by Negoro et al (see Ferrigno and Buccheri, 2000).

Multicenter randomised phase 3 trials as well as meta-analysis of IP chemotherapy have been performed and demonstrated that chemotherapy drugs administered intraperitoneally are superior to intravenous standard regimens in patient with optimally debulked epithelial ovarian cancer.

The one RCT was an open, multicenter and randomised phase III study with two parallel treatment groups.

Recently, a multicenter, open-label, randomised phase III trial (V325) was conducted to evaluate the safety and efficacy of docetaxel for treating patients with advanced gastric adenocarcinoma (Van Cutsem et al, 2006).

CHARISMA is a multicenter, randomized, phase III clinical trial.

We conducted a multicenter, placebo-controlled, double-blind, randomised phase II study to evaluate the effectiveness of aprepitant for preventing CINV after carboplatin- or irinotecan-based MEC in nondrinking women <70 years.

CALYPSO was an international randomised, phase III, open-label, multicenter trial.